Oncology- Our Service Offerings
Key Questions RAS Can Help You Answer
What is the current solid tumor clinical development landscape?
What are the key market impacting events?
What´s the strategy of major Oncology players?
What´s the positioning and strategy for a molecule of interest?
What are the upcoming innovation waves? What are the opportunities created by them?
What´s the current state-of-the-art in cancer biomarkers?
How to keep pace with the regulatory policies & payer positions across geographies?
What drug candidates/ companies are suitable for partnering or in-licensing for oncology therapeutics?
Featured Insights
Read Our Blogs
May 31, 2017
Merck will present data for KEYTRUDA® Across 16 Types of Cancer at the 2017 ASCO Annual Meeting Researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including NSCLC, melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric […]
May 31, 2017
Pfizer will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 moA, at the ASCO in Chicago from June 2-6, 2017. New data will be featured in 9 oral presentations from company-sponsored clinical trials, including a late-breaker on the investigational compound […]
May 31, 2017
Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative […]
May 30, 2017
Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies […]
May 30, 2017
AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology […]
May 30, 2017
Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic […]